# ArriVent BioPharma, Inc. (AVBP)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/AVBP/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 0 | $ -93.21M | $ -81.47M | $ 351.0K | $ 366.84M |
| 2025 | $ 0 | $ -170.28M | $ -164.43M | $ 14.0K | $ 307.22M |
| 2024 | $ 0 | $ -84.60M | $ -73.80M | $ 176.0K | $ 257.65M |
| 2023 | $ 0 | $ -74.97M | $ -60.38M | $ 317.0K | $ 151.30M |
| 2022 | $ 0 | $ -41.23M | $ -48.74M | $ 139.0K | $ 174.46M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.00 |
| Liabilities / Eq | 0.08 |
| Current Ratio | 14.16 |

## Other views

- [Metrics](https://sponda.capital/en/AVBP.md)
- [Charts](https://sponda.capital/en/AVBP/charts.md)
- [Compare](https://sponda.capital/en/AVBP/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-28.